Latest Communications

19 March 2012
Nautlius Neurosciences, Inc. Announces a New Approval for CAMBIA® in the Acute Treatment of Migraine

01 March 2012
APR Applied Pharma Research ("APR") and Labtec GmbH ("Labtec") announce the European approval of Zolmitriptan Oral Dispersible Film (ODF)

18 January 2012
APR Applied Pharma Research s.a. (“APR”), Labtec GmbH (“Labtec”) and Norgine BV (“Norgine”) announce the signature of an exclusive licensing agreement under which Norgine will market and distribute Setofilm™ Ondansetron Oral Dispersible Film (“ODF”), in Europe and selected non-European countries.


TOPICAL PHARMACEUTICALS

Integrated project development



GALENIC DEVELOPMENT

This phase foreseen the following activities:

> Pre-formulation development: the drug candidate/s is/are analyzed in terms of physical, chemical characteristics in order to identify the best excipients selection and the topical pharmaceutical form.

> Formulation design: APR is able to set up a range of hypothetical formulations based on its background to achieve the requested characteristics both in terms of release and in terms of chemical, physical, texture and taste aspect. Generally several possible formulations are taken into account during this phase in order to evaluate different prototypes that could give different results especially as it concerns the long terms stability both in terms of API degradation and in terms on stability of the vehicle base.

> Prototypes development: based on the pre-formulation development, formulation design and compatibility test, APR R&D team selects different formulation solutions based on its background united with the continuous research of innovation that permit us to find out the best formulation. The best topical form and its manufacturing method are set up on our laboratory equipment thinking at the successive technology transfer and the consequent scale up. All the manufacturing phases are under control also as it concerns the analytical aspect: in process control are managed by the analytical department laboratory which is at its complete service for a continuous and fast analytical support.

> Preliminary stability study: a preliminary stability study in stressed and/or ICH storage conditions can be performed on the hypothetical formulation, as adjunctive information before the selection of the formulation/s able to achieve the big laboratory batch/es production. Both the aspects characteristics and the degradation ones are evaluated during the study. The best conditions for the preliminary evaluations are defined case by case and they are established looking at each product and formulation and at further particular customers requests. In this phase, the analytical methods are set up and , in some case, validated according our internal procedures.

> Microbiological analysis: Microbial contamination of products is a matter of great importance. Frequently their water and other components content promote the growing of microorganism which often cause organoleptic and physicochemical alterations (offensive odours, changes in colour, viscosity, pH ...) or, in some case, the formation of substances potentially hazardous for the consumer. In order to detect this risk a pool of test are carried out according to pharmacopoeias and cosmetic organisations during all the estimated shelf life taking into account also the consumer use as source of contamination.

UP-SCALING & VALIDATION

This phase foreseen the following activities:

> Manufacturing of big-laboratory batch/es: the formulations, selected for their performances in terms of texture, appearance and stability, are manufactured as big laboratory batches. In this phase the GMP analytical laboratory supports the R&D departments managing the stability study according to the ICH conditions on these batches taking into account also the packaging aspect.

> Production of GMP batch for a clinical purpose: on the base of the stability results, winner prototype/s is/are selected for the GMP production, using a network of partners or the one selected by the costumer. A stability study according to the ICH guidelines is so performed on the GMP batch/es filled in the selected packaging; the formal technological and analytical transfer to the GMP facilities is managed by APR.

> The up scaling phase is closed by the manufacture of three validation batchs; a complete documentation of the performed activities is drawn up in order to prepare the Module 3 and/or the CMC.



CLINICAL PHASE

APR structure includes also a complete clinical department able to design clinical trial protocols and supervise and monitor execution of clinical studies using a network of partners or the one selected by the costumer.

REGISTRATION

APR is able to prepare a complete Dossier ready for the submission to the Health Authorities for a Registration purpose

Important note: Customer Reports describing all the activities performed and related results are monthly delivered, in this way customers have always the project under control to face the GO/NO GO decisions with all the necessary information.



Search results